New hope for bile duct cancer patients who have run out of options
NCT ID NCT07582315
First seen May 12, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tests a new drug called BL-B01D1 against standard treatments in about 538 people with advanced bile duct cancer that has worsened after chemotherapy and immunotherapy. The goal is to see if the new drug helps people live longer. Participants must be 18 to 75 years old and have a tumor that can be measured on scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.